Our data, derived from the public clinical trial source, over-represents the 'Pass' category for obvious reasons. But, since we provide the code to integrate drug-disease pair to its component target bioactivity, we expect other stakeholders like pharmaceutical companies and research agencies that have access to curated clinical trial datasets and a large body of in-house 'Fail' category trials to perform much better. Our work introduces this possibility for the first time and enables any researchers to repeat the study. It should be noted that the creation of the dataset is a significant effort, and we have enabled researchers to streamline that part of the workflow. In other words, 'small data' models presented in this study provide significant predictions to provide value towards predicting the possibility of a 'Pass'. Nonetheless, larger datasets will only enhance the predictive power of both classes of trials.